Why SLS stock is jumping premarket: SELLAS Life Sciences puts REGAL Phase 3 countdown back in play
New York, Feb 23, 2026, 05:32 EST — Premarket SELLAS Life Sciences Group Inc was up 3.4% at $4.29 ahead of the open on Monday, pushing higher after a run in the clinical-stage cancer drug developer’s shares.